Update on triple‐negative breast cancer disparities for the United States: A population‐based study from the United States Cancer Statistics database, 2010 through 2014-Reference-Cited by-同舟云学术

Update on triple‐negative breast cancer disparities for the United States: A population‐based study from the United States Cancer Statistics database, 2010 through 2014

Published:2019-07-08 Issue:19 Volume:125 Page:3412-3417
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Scott Lia C.¹^ORCID,Mobley Lee R.²,Kuo Tzy‐Mey³,Il’yasova Dora¹

Affiliation:

1. Division of Epidemiology and Biostatistics School of Public Health Georgia State University Atlanta Georgia

2. Department of Health Management and Policy, School of Public Health Georgia State University Atlanta Georgia

3. Statistics and Data Management, Cancer Information and Population Health Resource, Lineberger Cancer Center University of North Carolina at Chapel Hill Chapel Hill North Carolina

Funder

National Institute on Minority Health and Health Disparities

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32207

Reference23 articles.

1. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype

2. Disparities and Survival Among Breast Cancer Patients

3. Racial disparities in breast carcinoma survival rates

4. Breast Cancer in African-American Women

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New mono and dinuclear half-sandwiched organoruthenium(II) complexes: Effect of dinuclearity on the biomolecular interaction and cytotoxicity;Inorganica Chimica Acta;2024-09

2. Racial/ethnic differences in the clinical presentation and survival of breast cancer by subtype;Frontiers in Oncology;2024-08-16

3. Antibody and siRNA Nanocarriers to Suppress Wnt Signaling, Tumor Growth, and Lung Metastasis in Triple‐Negative Breast Cancer;Advanced Therapeutics;2024-05-08

4. Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer;Future Oncology;2024-04-25

5. Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany;Cost Effectiveness and Resource Allocation;2024-03-08